165 related articles for article (PubMed ID: 15635177)
1. Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats.
Kageyama M; Namiki H; Fukushima H; Terasaka S; Togawa T; Tanaka A; Ito Y; Shibata N; Takada K
Biol Pharm Bull; 2005 Jan; 28(1):130-7. PubMed ID: 15635177
[TBL] [Abstract][Full Text] [Related]
2. In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats.
Kageyama M; Namiki H; Fukushima H; Ito Y; Shibata N; Takada K
Biol Pharm Bull; 2005 Feb; 28(2):316-22. PubMed ID: 15684491
[TBL] [Abstract][Full Text] [Related]
3. Long-term pharmacokinetic efficacy and safety of low-dose ritonavir as a booster and atazanavir pharmaceutical formulation based on solid dispersion system in rats.
Fukushima K; Haraya K; Terasaka S; Ito Y; Sugioka N; Takada K
Biol Pharm Bull; 2008 Jun; 31(6):1209-14. PubMed ID: 18520056
[TBL] [Abstract][Full Text] [Related]
4. Time-dependent interaction of ritonavir in chronic use: the power balance between inhibition and induction of P-glycoprotein and cytochrome P450 3A.
Fukushima K; Kobuchi S; Mizuhara K; Aoyama H; Takada K; Sugioka N
J Pharm Sci; 2013 Jun; 102(6):2044-2055. PubMed ID: 23589366
[TBL] [Abstract][Full Text] [Related]
5. Modulation of P-glycoprotein expression by cytochrome P450 3A inducers in male and female rat livers.
Salphati L; Benet LZ
Biochem Pharmacol; 1998 Feb; 55(4):387-95. PubMed ID: 9514072
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
[TBL] [Abstract][Full Text] [Related]
7. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
[TBL] [Abstract][Full Text] [Related]
9. Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats.
Perloff MD; von Moltke LL; Greenblatt DJ
Xenobiotica; 2004 Feb; 34(2):133-50. PubMed ID: 14985144
[TBL] [Abstract][Full Text] [Related]
10. Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. II: establishment and evaluation of dexamethasone-pretreated female rats.
Kanazu T; Yamaguchi Y; Okamura N; Baba T; Koike M
Xenobiotica; 2004 May; 34(5):403-13. PubMed ID: 15370957
[TBL] [Abstract][Full Text] [Related]
11. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.
Huang L; Wring SA; Woolley JL; Brouwer KR; Serabjit-Singh C; Polli JW
Drug Metab Dispos; 2001 May; 29(5):754-60. PubMed ID: 11302944
[TBL] [Abstract][Full Text] [Related]
12. Mdr1 limits CYP3A metabolism in vivo.
Lan LB; Dalton JT; Schuetz EG
Mol Pharmacol; 2000 Oct; 58(4):863-9. PubMed ID: 10999959
[TBL] [Abstract][Full Text] [Related]
13. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.
Backman JT; Kivistö KT; Olkkola KT; Neuvonen PJ
Eur J Clin Pharmacol; 1998 Mar; 54(1):53-8. PubMed ID: 9591931
[TBL] [Abstract][Full Text] [Related]
14. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
[TBL] [Abstract][Full Text] [Related]
15. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.
van Waterschoot RA; ter Heine R; Wagenaar E; van der Kruijssen CM; Rooswinkel RW; Huitema AD; Beijnen JH; Schinkel AH
Br J Pharmacol; 2010 Jul; 160(5):1224-33. PubMed ID: 20590614
[TBL] [Abstract][Full Text] [Related]
16. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.
Hafner V; Jäger M; Matthée AK; Ding R; Burhenne J; Haefeli WE; Mikus G
Clin Pharmacol Ther; 2010 Feb; 87(2):191-6. PubMed ID: 19924124
[TBL] [Abstract][Full Text] [Related]
17. Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
Peltoniemi MA; Saari TI; Hagelberg NM; Reponen P; Turpeinen M; Laine K; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 2011 Aug; 90(2):296-302. PubMed ID: 21716267
[TBL] [Abstract][Full Text] [Related]
18. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects.
Penzak SR; Robertson SM; Hunt JD; Chairez C; Malati CY; Alfaro RM; Stevenson JM; Kovacs JA
Pharmacotherapy; 2010 Aug; 30(8):797-805. PubMed ID: 20653355
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of cyclosporine after orthotopic liver transplantation.
Fabre JM; Pedrosa R; Bonardet A; Pichard L; Descomps B; Domergue J; Baumel H; Maurel P
Biochem Pharmacol; 1993 Oct; 46(7):1151-7. PubMed ID: 8216365
[TBL] [Abstract][Full Text] [Related]
20. Effects of sinapic acid on hepatic cytochrome P450 3A2, 2C11, and intestinal P-glycoprotein on the pharmacokinetics of oral carbamazepine in rats: Potential food/herb-drug interaction.
Raish M; Ahmad A; Ansari MA; Alkharfy KM; Ahad A; Al-Jenoobi FI; Al-Mohizea AM; Khan A; Ali N
Epilepsy Res; 2019 Jul; 153():14-18. PubMed ID: 30927680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
